Medication info
Lyribea Capsule 300mg (Pregabalin)

Lyribea Capsule 300mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›300mg / 1 capsule
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Capsule with a reddish-brown upper part and a white lower part containing white or light yellow powder.
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201706387 · Approved 2017.07.31 · Insurance code 694001440

Summary

Main use
Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
The total daily dose of this medication, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg per day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg per day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to ‘4. Discontinuation of administration’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg per day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosage regimen. b: A supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Children under 12 years and adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain; adjunctive treatment of partial-onset seizures; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medicine is used to treat peripheral and central neuropathic pain in adults. It is also effective as an adjunct in adults with epilepsy, especially those with partial seizures. Additionally, it helps alleviate symptoms of chronic pain conditions such as fibromyalgia. In summary, this drug is used for the treatment of nerve-related pain, certain seizures, and fibromyalgia.

How to take

Adult dose

The total daily dose of this medication, as pregabalin, is administered orally in 2 divided doses, with or without food. Since this medication is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg per day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg per day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, a dose reduction may be considered. (Refer to ‘4. Discontinuation of administration’) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg per day. Depending on the individual patient’s response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys unchanged. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For women, multiply the result obtained from the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60 150 600 BID or TID ≥30 -<60 75 300 BID or TID ≥15 -<30 25-50 150 QD or BID <15 25 75 QD Supplemental dose after hemodialysis 25 100 Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosage regimen. b: A supplemental dose refers to a dose administered once in addition to the regular dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Children under 12 years and adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, patients should consult a doctor immediately if they experience depression or mood changes during treatment. Patients with hypersensitivity to this medication or lactose intolerance should not take it. Diabetic patients may need to adjust their blood glucose control medications due to potential weight gain. If allergic reactions such as angioedema occur, medication should be discontinued immediately. Elderly patients should be particularly cautious during the early stages of treatment due to the risk of careless accidents from dizziness or drowsiness. Blurred vision or changes in vision may occur, and patients should consult a doctor if symptoms arise. Discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, and anxiety, so it should be tapered off according to a doctor's instructions. There is a risk of drug abuse; therefore, patients with a history of substance abuse should be monitored closely. Patients with impaired kidney function may require dose adjustments. Patients with heart disease should be closely monitored while taking this drug. Caution is advised when used with opioid analgesics due to the enhanced central nervous system depressive effects, which may lead to respiratory depression. During early pregnancy, there is a risk of fetal deformities, so this medication should be avoided during pregnancy, and fertile women should use effective contraception. Breastfeeding women should either avoid this medication or discontinue breastfeeding, as it may be transmitted through breast milk and affect the baby. Caution is required when driving or operating dangerous machinery due to the risks of dizziness and drowsiness. In case of overdose, symptoms such as confusion, drowsiness, or seizures may occur, and immediate medical attention is necessary. Keep this medicine out of the reach of children and avoid transferring it to other containers. If severe rashes or swelling occur on the skin during the course of this medication, discontinue usage immediately and consult a doctor.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper respiratory tract swelling
  • dizziness
  • drowsiness
Show 210 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • melancholy
  • thoughts of suicide
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual sensation disorder
  • restlessness
  • anxiety
  • mood swings
  • emotional decline
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • motor coordination disorder
  • balance disorders
  • amnesia
  • attention disorders
  • memory disorders
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory decline
  • sedation
  • somnolence
  • cognitive dysfunction
  • nystagmus
  • speech disorders
  • myoclonic jerks
  • diminished reflexes
  • abnormal movements
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • ocular swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • ocular irritation
  • mydriasis
  • during vibration
  • changes in depth perception of vision
  • strabismus
  • brightness of vision
  • vertigo
  • hyperacusis
  • first-degree heart block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • flatulence
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory decline
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary dysfunction
  • urinary incontinence
  • reduced urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • affective disorder
  • drowsiness
  • confusional state
  • depression
  • agitation
  • restlessness
  • exacerbation of seizures
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin disorders
  • increased BUN
  • bloody stools
  • colorectal cancer
  • gastroenteritis
  • pneumonia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture. A cool place with a temperature between 15 and 30 degrees Celsius is suitable for storage.

Appearance and packaging

Appearance

Capsule with a reddish-brown upper part and a white lower part containing white or light yellow powder.

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.